How CMTM6 Causes Resistance to Gemcitabine in Pancreatic Cancer
Author Information
Author(s): Zhu Ying‐Qin, Huang Yue, Shi Yin‐Hao, Huang Chen‐Song, Zhao Guang‐Yin, Liu Zhi‐De, Ma Ming‐Jian, Ye Jing‐Yuan, Xu Xiang, Liu Qi, Huang Xi‐Tai, Wang Jie‐Qin, Xu Qiong‐Cong, Yin Xiao‐Yu
Primary Institution: The First Affiliated Hospital of Sun Yat‐sen University
Hypothesis
The study investigates the role of the CMTM6-IGF2BP1-EP300 feedback loop in gemcitabine resistance in pancreatic ductal adenocarcinoma.
Conclusion
The EP300-CMTM6-IGF2BP1 feedback loop enhances gemcitabine resistance in pancreatic cancer, suggesting that targeting this loop may improve treatment outcomes.
Supporting Evidence
- CMTM6 is upregulated in gemcitabine-resistant pancreatic cancer cell lines.
- EP300-mediated H3K27ac modification activates CMTM6 transcription.
- CMTM6 enhances tumor stemness and contributes to gemcitabine resistance.
- Combined treatment with EP300 inhibitor inobrodib and gemcitabine shows synergistic effects.
- High CMTM6 expression correlates with poor prognosis in pancreatic cancer patients.
Takeaway
This study found that a protein called CMTM6 helps pancreatic cancer cells resist a common chemotherapy drug, gemcitabine, and blocking this protein could make the treatment work better.
Methodology
The study used patient-derived xenograft models and RNA sequencing to analyze gene expression related to gemcitabine resistance.
Potential Biases
Potential biases may arise from the selection of cell lines and patient samples.
Limitations
The study primarily focuses on in vitro and in vivo models, which may not fully replicate human responses.
Participant Demographics
Patients with pancreatic ductal adenocarcinoma who had not received prior chemotherapy.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website